幽門螺桿菌感染通常沒有症狀。
幽門螺旋桿菌影響了近一半人口(5,9)，幽門螺旋桿菌感染可導致胃炎和消化性潰瘍病(11-14)，它亦提高了患胃癌的風險達2至6倍(1)。
幽門螺桿菌的標準治療涉及多種抗生素組合配合胃藥一起服用，但有證據顯示抗生素耐藥性正在蔓延，總體療效漸漸被降低[16,17]。
日本研究人員開發了一種天然療法，透過礦物質鋅和肌肽(一種由兩個氨基酸組成的二肽）的組合，可有效去除幽門螺旋桿菌，同時有效修復它對腸胃道所造成的傷害。
另外，一種名為羅伊氏乳桿菌(L. Reuteri)的特定益生菌菌株也被證明可以減少幽門螺桿菌滋長。
這些非藥物方法可以安全地抑制幽門螺旋桿菌，修復胃壁潰瘍，降低炎症，緩解慢性胃病。值得一試。
Helicobacter pylori (H. pylori) is a major cause of gastritis and ulcers.1-7
The two scientists who discovered this were awarded the Nobel Prize in Physiology or Medicine.8
Infection with the H. pylori bacteria is often without symptoms.1
H. pylori affects almost 50% of the population.5,9 It boosts the risk of stomach cancer10 by two- to six-fold,1 and can cause gastritis and peptic ulcer disease.11-14
Standard treatment for H. pylori involves a powerful antibiotic combination,15 but antibiotic resistance has reduced overall efficacy.16,17
Japanese researchers have developed a combination of zinc and carnosine that removes H. pylori while healing the damage it has caused.
A specific probiotic strain called Lactobacillus reuteri has also been shown to reduce H. pylori bacteria.
This non-drug approach can safely inhibit H. pylori, heal the stomach lining, lower inflammation, and alleviate chronic stomach problems.
References
1, Available at: http://www.cdc.gov/ulcer/files/hpfacts.pdf. Accessed July 16, 2018.
2, Available at: http://emedicine.medscape.com/article/176156-overview. Accessed July 16, 2018.
3, Available at: http://www.cancer.gov/about-cancer/causes-prevention/risk/infectious-agents/h-pylori-fact-sheet. Accessed July 16, 2018.
4, Lopes D, Nunes C, Martins MC, et al. Eradication of Helicobacter pylori: Past, present and future. J Control Release. 2014;189:169-86.
5, Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut. 2012;61(5):646-64.
6, Meurer LN, Bower DJ. Management of Helicobacter pylori infection. Am Fam Physician. 2002;65(7):1327-36.
7, Wu TS, Hu HM, Kuo FC, et al. Eradication of Helicobacter pylori infection. Kaohsiung J Med Sci. 2014;30(4):167-72.
8, Available at: https://www.nobelprize.org/nobel_prizes/medicine/laureates/2005/press.html. Accessed July 13, 2018.
9, Lee YC, Chiang TH, Chou CK, et al. Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis. Gastroenterology. 2016;150(5):1113-24 e5.
10, Peek RM, Jr. New Biology to New Treatment of Helicobacter pylori-Induced Gastric Cancer. Dig Dis. 2016;34(5):510-6.
11, Available at: http://emedicine.medscape.com/article/175909-overview#a4. Accessed July 16, 2018.
12, Available at: https://www.niddk.nih.gov/health-information/digestive-diseases/gastritis. Accessed July 13, 2018.
13, Varbanova M, Malfertheiner P. Bacterial load and degree of gastric mucosal inflammation in Helicobacter pylori infection. Dig Dis. 2011;29(6):592-9.
14, Available at: http://emedicine.medscape.com/article/181753-overview#showall. Accessed July 16, 2018.
15, Bohr UR, Malfertheiner P. Eradication of H. pylori Infection: the Challenge is on if Standard Therapy Fails. Therap Adv Gastroenterol. 2009;2(1):59-66.
16, Hsu PI, Wu DC, Chen WC, et al. Randomized controlled trial comparing 7-day triple, 10-day sequential, and 7-day concomitant therapies for Helicobacter pylori infection. Antimicrob Agents Chemother. 2014;58(10):5936-42.
17, Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012;5:151-7.
No comments:
Post a Comment